Complex actions of sodium glucose transporter-2 inhibitors on lipids, calcific atherosclerosis, and bone density DOI
Stuti Pradhan,

Sophia Kalanski,

Yin Tintut

и другие.

Current Opinion in Lipidology, Год журнала: 2024, Номер 35(5), С. 253 - 257

Опубликована: Июль 18, 2024

Purpose of review Inhibitors sodium-glucose cotransporter-2 (SGLT2) lower renal glucose reabsorption and, thus, are used to treat patients with type 2 diabetes mellitus. Clinical trials coincidentally showed that SGLT2 inhibitors also benefitted heart failure. This explores the impact on other aspects cardiovascular disease and skeletal health. Recent findings In some, but not all, clinical preclinical studies, found reduce serum levels free fatty acids triglycerides. Their effects total low-density lipoprotein cholesterol cardiac function vary. However, lipid accumulation in liver, kidney, heart, alter expression metabolism genes. Effects acid uptake abdominal fat depots depend location adipose tissue. male, female, mice, atherosclerotic lesions aortic calcium deposition. With respect health, recent literature has reported conflicting associations risks fracture amputation. Summary Studies suggest tissue accumulation, a sex-dependent manner, atherosclerosis vascular calcification. their bone health complex remain be established.

Язык: Английский

Repurposing Mitochondria-Targeted Therapeutics for Kidney Diseases DOI
Austin Thompson, Sivasankaran Ponnusankar, Natalie E. Scholpa

и другие.

Kidney International, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0
Complex actions of sodium glucose transporter-2 inhibitors on lipids, calcific atherosclerosis, and bone density DOI
Stuti Pradhan,

Sophia Kalanski,

Yin Tintut

и другие.

Current Opinion in Lipidology, Год журнала: 2024, Номер 35(5), С. 253 - 257

Опубликована: Июль 18, 2024

Purpose of review Inhibitors sodium-glucose cotransporter-2 (SGLT2) lower renal glucose reabsorption and, thus, are used to treat patients with type 2 diabetes mellitus. Clinical trials coincidentally showed that SGLT2 inhibitors also benefitted heart failure. This explores the impact on other aspects cardiovascular disease and skeletal health. Recent findings In some, but not all, clinical preclinical studies, found reduce serum levels free fatty acids triglycerides. Their effects total low-density lipoprotein cholesterol cardiac function vary. However, lipid accumulation in liver, kidney, heart, alter expression metabolism genes. Effects acid uptake abdominal fat depots depend location adipose tissue. male, female, mice, atherosclerotic lesions aortic calcium deposition. With respect health, recent literature has reported conflicting associations risks fracture amputation. Summary Studies suggest tissue accumulation, a sex-dependent manner, atherosclerosis vascular calcification. their bone health complex remain be established.

Язык: Английский

Процитировано

0